{"id":408968,"date":"2021-01-05T16:08:42","date_gmt":"2021-01-05T21:08:42","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408968"},"modified":"2021-01-05T16:08:42","modified_gmt":"2021-01-05T21:08:42","slug":"xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/","title":{"rendered":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference"},"content":{"rendered":"

<\/p>\n

Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference<\/b><\/p>\n

CHICAGO–(BUSINESS WIRE<\/a>)–
\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the H.C. Wainwright BioConnect 2021 virtual conference being held January 11-14, 2021.\n<\/p>\n

\nA webcast of the on-demand presentation will be available beginning January 11, 2021 at 6:00 a.m. E.T. through the investors section on the Company’s website at www.xerispharma.com<\/a>.\n<\/p>\n

About Xeris Pharmaceuticals, Inc.<\/b><\/p>\n

\nXeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.\n<\/p>\n

\nWith a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke\u00ae. Its proprietary XeriSol\u2122 and XeriJect\u2122 formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris\u2019 technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.\n<\/p>\n

\nXeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com<\/a>, or follow us on Twitter<\/a>, LinkedIn<\/a> or Instagram<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210105005826\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
Allison Wey
\n
Senior Vice President, Investor Relations and Corporate Communications
\n
awey@xerispharma.com<\/a><\/p>\n

KEYWORDS:<\/b> Illinois United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Diabetes General Health Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference CHICAGO–(BUSINESS WIRE)– Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the H.C. Wainwright BioConnect 2021 virtual conference being held January 11-14, 2021. A webcast of the on-demand presentation will be available beginning January 11, 2021 at 6:00 a.m. E.T. through the investors section on the Company’s website at www.xerispharma.com. About Xeris Pharmaceuticals, Inc. Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important … <\/p>\n

Continue reading “Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408968","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nXeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference CHICAGO–(BUSINESS WIRE)– Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the H.C. Wainwright BioConnect 2021 virtual conference being held January 11-14, 2021. A webcast of the on-demand presentation will be available beginning January 11, 2021 at 6:00 a.m. E.T. through the investors section on the Company’s website at www.xerispharma.com. About Xeris Pharmaceuticals, Inc. Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important … Continue reading "Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T21:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference\",\"datePublished\":\"2021-01-05T21:08:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"name\":\"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-05T21:08:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk","og_description":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference CHICAGO–(BUSINESS WIRE)– Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the H.C. Wainwright BioConnect 2021 virtual conference being held January 11-14, 2021. A webcast of the on-demand presentation will be available beginning January 11, 2021 at 6:00 a.m. E.T. through the investors section on the Company’s website at www.xerispharma.com. About Xeris Pharmaceuticals, Inc. Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important … Continue reading \"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T21:08:42+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference","datePublished":"2021-01-05T21:08:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"wordCount":309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/","name":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-05T21:08:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210105005826r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-pharmaceuticals-to-participate-in-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408968"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408968\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}